Clinical Trial Update: A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating MDMA-assisted psychotherapy for posttraumatic stress disorder has completed across multiple sites, with results posted in October 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Posttraumatic Stress Disorder

Drugs mentioned

• MDMA (3,4-methylenedioxymethamphetamine)

Snippet

Sponsor: Lykos Therapeutics | Conditions: Posttraumatic Stress Disorder | Phase 3 | Status: COMPLETED | Results posted: 2023-10-11